At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, and 3 other interventions for West Nile Fever. Completed, enrolled 208 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease. The study is divided into two parts; in the first part, a comparison of 3 dose levels of the vaccine will be made, with an inactive control. In the second part, the optimum dose level chosen after the first part will be given to older volunteers.
Study Details
Timeline
Interventions
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region